

## **Scott Fountain, Ph.D.**

Executive Director and General Manager  
Charles River Laboratories

### **From Service Provider to Portfolio Partner – R&D Collaboration in Addressing Patient Need**



Dr. Scott Fountain is currently Executive Director and General Manager of the Charles River Laboratories facility in Shrewsbury, Massachusetts. In this role, Scott is responsible for the financial, operational, scientific, and regulatory performance of the Discovery, Pharmacology, Safety Assessment, and Laboratory Sciences businesses at this facility. Prior to joining Charles River, Scott was Executive Director of Biotherapeutics and Translational Research in the Department of Pharmacokinetics, Dynamics, and Metabolism (PDM) at Pfizer San Diego, where he established and led a core group integrating quantitative bioanalysis and mathematical modeling & simulation to advance Pfizer's large molecule portfolio.

Scott earned his BS in Chemistry from Central Michigan University and his PhD in Analytical Chemistry from The University of Michigan in Ann Arbor. After graduation, Scott worked for Waters Corporation as a Senior Applications Chemist in Beverly, Massachusetts. In 1998, he joined Pfizer Global Research & Development in Michigan to establish a quantitative LC/MS/MS laboratory in the Pharmacokinetics & Drug Metabolism research line, supporting small molecule PK and biomarker research.

Scott is an active volunteer in the scientific community, including the American Association of Pharmaceutical Sciences (AAPS) and the Boston Society Applied Pharmaceutical Analysis organizations, where he served as 2017 BIOTEC Section Chair and 2016 APA Conference Chair, respectively.

**AAPS Northeast Regional Discussion Group (NERDG) 2020 Annual Meeting**

**Justin Hanes, Ph.D.**  
Lewis J. Ort Professor  
Director, The Center for Nanomedicine at the Wilmer Eye Institute  
Johns Hopkins University School of Medicine  
**Translation of Advanced Drug Delivery Technologies**



Justin Hanes is the Lewis J. Ort Professor and Director of the Center for Nanomedicine at the Johns Hopkins University. He holds faculty appointments in the departments of Ophthalmology, Biomedical Engineering, Chemical & Biomolecular Engineering, Neurosurgery, Oncology, and Pharmacology & Molecular Sciences.

He is the current President of the Controlled Release Society.

He is an inventor on more than 125 patents and patent applications focused in the area of advanced drug and gene delivery systems. Multiple products based on these patents have been approved by the US FDA and are helping millions of patients. Dr. Hanes has co-founded 10 pharmaceutical companies, and they have more than 10 different drugs in ongoing or planned Phase 2 or 3 human clinical trials.

Dr. Hanes is also a Venture Partner with Camden Partners where he serves as the Chief Scientist of the Camden Partners Nexus Fund.

Dr. Hanes was inducted into the National Academy of Inventors in 2014 and is a fellow of the American Association of Pharmaceutical Scientists (AAPS). Awards he has received from the AAPS include the Ebert Prize and the Innovation in Biotechnology Award (which he has won twice). He has been named among “The World’s Top 100 Young Innovators and Leaders in Technology and Business” by the *MIT Technology Review*, “The World’s Most Influential Scientific Minds” by Thompson Reuters (multiple times), and an Edward C. Nagy Investigator by the National Institute of Biomedical Imaging and Bioengineering of the NIH. His degrees are in Chemical Engineering from UCLA (B.S. 1991) and MIT (Ph.D. 1996), and he completed a postdoctoral fellowship in Oncology and Neurosurgery at Johns Hopkins prior to joining the faculty of the Johns Hopkins University in 1998.

**AAPS Northeast Regional Discussion Group (NERDG) 2020 Annual Meeting**